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Figure 1. Simplified view of the effect of 
susceptibility of the heart to I/R injury. Conditions 
that increase cellular damage render the heart more 
susceptible to injury while those that decrease 
myocardial injury convey cardioprotection.  
Introduction 
Ischemia reperfusion injury (I/R) underlies a plethora of pathologies from spinal 
cord injury to myocardial infarction 
(MI). Ischemia is a restriction of 
blood flow to tissues and is often 
followed by reperfusion, or the 
return of blood flow. 
Ectonucleoside triphosphate 
diphosphohydrolase 1 (CD39) is 
an innate cardiovascular, blood, 
and vasculature protective protein. 
Genetic deletion of CD39 results in loss of the inherent cardioprotection and 
increases the extent of heart tissue injury after induced MI compared to wild-type 
mice.  As depicted in Figure 1, conditions that provide cardioprotection confer a 
reduced infarct size whereas conditions that increase susceptibility to injury result 
in a larger infarct.  Administration of apyrase, a CD39-like molecule, protects the 
heart, decreasing damage after MI.16 However, whether increased CD39 
conveys cardioprotection in an isolated heart perfusion, without the complicating 
factors of blood and hormonal influences has not been determined. 
 
CD39, an endothelial cell-expressed enzyme, rapidly converts ATP and the 
prothrombotic molecule ADP to AMP.19 AMP is further degraded by another 
enzyme, CD73, to adenosine which is anti-thrombotic, vasodilatory, and 
cardioprotective.19  Administered adenosine is cardioprotective in animal models 
of ischemia-reperfusion injury.17 Clinical studies have shown that reduced CD39 
activity in coronary atherosclerotic lesions predisposes patients to vascular 
events wherein CD39 is decreased in lesions with unstable angina compared 
with those with stable angina. 22 
 
Hypothesis 1: CD39 overexpression mediates cardioprotection, attenuating 
ischemia/reperfusion (I/R) injury ex vivo, decreasing infarct size. 
 Specific Aim 1: To define the effect of CD39 activity on infarct size 
following I/R injury. 
 Anticipated Results: Infarct size will be reduced in CD39TG isolated 
hearts compared to wildtype. 
 
Hypothesis 2: CD39 overexpression mediates cardioprotection, attenuating 
ischemia/reperfusion injury, by increasing adenosine levels in the heart.  
Specific Aim 2: To define the effect of CD39 activity on ATP, ADP, 
AMP, and adenosine levels following 30 minutes of ischemia and 15 minutes 
of reperfusion in isolated hearts. 
Anticipated Results: Adenosine levels will be increased in CD39TG 
isolated hearts compared to wildtype with a consequent decrease in ATP, 
ADP, and AMP. 
 
Hypothesis 3: CD39 overexpression mediates cardioprotection, attenuating 
ischemia/reperfusion injury, via the RISK (Reperfusion Injury Salvage Kinase) 
pathway. 
 Specific Aim 3: To examine activated levels of AKT, ERK, and 
deactivation of GSK by examining phosphorylation of these proteins in heart 
tissue homogenate after ex vivo I/R injury. 
 Anticipated Results: Phosphorylation will be increased in varying 
degrees in AKT, ERK, and GSK in CD39TG tissue consistent with activation 
of the RISK pathway.  
 
 
A mouse model of global overexpression of human CD39 (CD39TG) was utilized 
in these experiments.  The ex vivo technique of excising the heart and perfusing 
it retrograde using a Langendorff perfusion apparatus allows for investigation of 
CD39 overexpression only in the heart tissue.  After subjecting CD39TG and 
wildtype hearts to I/R injury, three analyses were conducted to investigate the 
specific aims described above: 1) infarct size; 2) adenine nucleotide 
determination by HPLC; 3) RISK protein analysis by Western blotting.  
	  
Methods 
Langendorff-perfused heart preparation 9,25,26: Briefly, mice were anesthetized 
with ketamine (55mg/kg) and xylazine (15mg/kg), and hearts were excised, 
aortas were cannulated, and hearts were perfused in a Langendorff mode at a 
constant pressure of 80 mmHg with a modified Krebs-Henseleit buffer (KHB) 
equilibrated with 95% O2-5% CO2 at 37°C (Figure 2). The constituents of KHB 
are (in mM) 120 NaCl, 5.9 KCl, 25 NaHCO3, 1.2 MgCl2, 2.5 CaCl2, 0.5 EDTA, 
and 16.7 glucose. A fluid-filled balloon was inserted into the left ventricle (LV) 
across the mitral valve and 
connected to a pressure transducer 
permitting continuous measurement 
of LV pressure (LVP). Hearts were 
immersed in a water-jacketed bath 
maintained at 37°C, and the LV 
balloon was filled with water to yield 
a LV diastolic pressure of 3–6 
mmHg.  Aortic pressure and LV 
developed pressure (LVDP) was 
Figure	  2.	  	  Schematic	  of	  a	  Langendorff	  heart	  perfusion	  setup	  modified	  from	  Sutherland	  and	  Hearse	  website:	  http://www.southalabama.edu/ishr/help/hearse/	  
recorded on a PowerLab/400 multichannel data acquisition system 
(ADInstruments). The LVP signal was digitally processed (using PowerLab Chart 
software version 4.2; ADInstruments) to yield diastolic and systolic pressures as 
well as heart rate. Hearts having unexpected arrhythmias during equilibration 
were excluded from the study.  Hearts were subjected to one of three protocols 
(Figure 3). For infarct analysis hearts underwent 30 minutes perfusion 
(equilibration), 30 minutes ischemia, followed by 60 minutes of reperfusion.  For 
baseline HPLC and Western blot analysis, hearts underwent 60 minutes of 
equilibration. HPLC and Western blot injured hearts underwent 30 minutes 
equilibration, 30 minutes of ischemia, followed by 15 minutes of reperfusion.  To 
induce ischemia, perfusion to the heart was stopped for a designated period.  
Flow of the Krebs-Henseleit buffer was restored for reperfusion. 
 
 
 
Infarct Assessment: Following I/R injury, 1% 2,3,5-triphenyltetrazolium chloride 
(TTC) was pushed through an aortic cannula to stain viable tissue. (TTC stains 
viable myocardium red and the area of infarction remains pale). The heart was 
sectioned and each cross-section was weighed.  Infarcts were measured using 
the computer program MetaVue.  Briefly, photographs of cross-sections of the 
Figure 3. Timeline for Langendorff perfused hearts where blue represents 
equilibration, green represents ischemia, and yellow represents reperfusion. 	  
ventricles were taken under a microscope and the image was transferred into 
MetaVue. Measurements of the total cross-sectional area, lumen, and infarct 
were collected and the percent of infarct was calculated. The measurements 
were repeated for the reverse side of the cross- section for accuracy, and 
reported as percent infarcted tissue per area at risk.  The area at risk and the 
infarct size were normalized to the sample weight. 
 
Measurement of ATP, ADP, AMP, Adenosine using HPLC: Unless stated all 
chemicals were obtained from Sigma Aldrich, St. Louis, MO.  Mouse hearts were 
flash frozen with stainless steel mortar and pestel and stored in liquid nitrogen. 
Samples were fragmented under liquid nitrogen with ceramic mortar and pestel, 
homogenized with ice cold 0.4 M perchloric acid in a glass Dounces 
homogenizer for 2 minutes on ice (mg pulverized tissue x 3 = volume perchloric 
acid). The homogenate was neutralized with 0.4M potassium phosphate dibasic 
(mg pulverized tissue x 3 = volume dibasic) and incubated on ice for 10 minutes. 
The homogenate was spun at 16,000g for 5 minutes at 4°C. The supernatant 
was removed and centrifuged in a 0.5 micron nylon filter at 16,000g for 5 minutes 
at 4°C.  50 µl of the processed homogenate was loaded into HPLC tubes. 
Standards were processed in the same manner and utilized to obtain a standard 
curve (GraphPad Prizm) from which the concentration of the adenine 
nucleotides, reported in µmol/mg protein, are calculated using linear regression 
then normalized to protein using the following equation: 
 
[Average conc. Adenine nucleotide (µmole/L)]  / [Protein conc. (mg/L)]  = 
         conc. µmol/mg protein 
Figure 4 provides a spec of the HPLC standards data from which the standard 
curve was obtained. 
 
 
Western Blot Analysis: On ice, 400 µl homogenizing buffer and 8 µl protease 
inhibitor were added to each frozen half of a heart.  Samples were homogenized, 
solubilized for 30 minutes, and centrifuged at 13,000 rpm for 10 minutes.  
Supernatant was added to glycerol so the final concentration of glycerol is 10%.  
Aliquots were frozen at -80°C for subsequent analysis.  Equal concentrations of 
protein verified by Coomassie staining were loaded onto SDS PAGE gels and 
transferred to nitrocellulose membrane overnight at 4°C. Membranes were rinsed 
and blocked with 5% blocking buffer (5g dried milk, 0.3g NaCl, 95 ml autoclaved 
Figure	  4.	  HPLC	  data	  obtained	  for	  10µM	  concentration	  of	  ATP,	  ADP,	  AMP,	  and	  adenosine.	  	  2µM,	  5µM,	  and	  10µM	  standards	  were	  obtained	  to	  generate	  standard	  curves.	  
water, and 5 ml 1M Tris pH 7.5) for 2 hours with agitation.  Primary antibodies 
(see Table 1) were added in blocking buffer to the membranes and incubated 
overnight at 4°C. Membranes then were rinsed for one hour with TBS with 0.05% 
Tween, and anti-rabbit secondary antibodies in 5% blocking buffer were added 
for 45 minutes (1:5,000) at room temperature.  After a one hour rinse with TBS 
with 0.05% Tween, Supersignal (Pierce) was added to each membrane for five 
minutes.  Kodak Biomax film was then exposed to membranes and developed.  
Results are quantified using Quantity One software on a BioRad ChemiDoc.  
 
Table 1. Antibodies for Western blot analysis of RISK pathway proteins. 
Antibody Company Catalog # Antibody type Dilution 
GAPDH Cell Signaling 2118 Rabbit 
Monoclonal 
1:5,000 
Akt Cell Signaling 9272  Rabbit 
Polyclonal 
1:5,000 
Akt-P-ser Cell Signaling 9271 Rabbit 
Polyclonal 
1:1,000 
GSK Cell Signaling 9315 Rabbit 
Monoclonal 
1:1,000 
GSK-P Cell Signaling 9322 Rabbit 
Monoclonal 
1:1,000 
Erk Cell Signaling 4695 Rabbit 
Monoclonal 
1:1,000 
Erk-P Cell Signaling 9101 Rabbit 
Monoclonal 
1:1,000 
 
Results 
Infarct Analysis 
An isolated Langendorff mouse model of myocardial infarction was used to 
determine the effect of CD39 overexpression without blood and hormonal 
influences.  We measured myocardial infarct size in CD39TG mice compared to 
WT mice after 30 minutes ischemia and 60 minutes reperfusion as shown in 
Figure 5.  Again, TTC stains viable tissue red, whereas infarcted (dead) tissue 
will not retain the dye and appears pale.  Thus, infarcts were measured as an 
indication of the extent of cardiovascular injury. The average percent of infarct 
tissue in WT mice (57 +/- 5%) was significantly greater (p < 0.0001) than the 
average infarct seen in CD39TG mice (21 +/- 2%).   
Ex vivo Infarct Size  
                                      
         
 
Adenine Nucleotide Analysis 
To assess the effect of overexpression of CD39, we measured the levels of ATP, 
ADP, AMP, and adenosine in Langendorff perfused wildtype and transgenic 
Figure 5. Infarct size seen in WT and CD39TG mice (C57 background) following ex vivo 30 
minutes ischemia and 60 minutes reperfusion.  Above each bar are representative infarct 
sections. Staining after I/R injury leaves viable tissue red and infarct pale. N = 6/group 	  
hearts at baseline and following I/R injury.  ATP concentrations measured in 
µmol/mg protein were taken for WT and CD39TG at both baseline and after 30 
minutes ischemia followed by 15 minutes reperfusion.  At baseline, the mean 
concentration of ATP in WT hearts (0.0374 +/- 0.0056 µmol/mg protein) was 
higher but not significantly different from ATP concentration of CD39TG hearts 
(0.0182 +/- 0.0079 µmol/mg protein).  Following I/R injury the mean 
concentration of 
ATP in WT hearts 
(0.0242 +/- 0.0027 
µmol/mg protein) 
was not 
significantly higher 
than ATP levels in 
CD39TG hearts 
(0.0177 +/- 0.0031 
µmol/mg protein).  
Figure 6. 
 
 
At baseline, the mean concentration of ADP in WT hearts (0.0473 +/- 0.0091 
µmol/mg protein) was greater but not significantly different than in CD39TG 
Figure 6. HPLC measurements of ATP in WT and CD39TG ex vivo hearts after 30 minutes 
ischemia and 15 minutes reperfusion. N=3/group 	  
hearts (0.0183 +/- 0.0099 µmol/mg protein).  Following I/R injury, the mean 
concentration of ADP in WT hearts (0.0206 +/- 0.0037 µmol/mg protein) was not 
significantly different than ADP levels in CD39TG hearts (0.0120 +/- 0.0057 
µmol/mg protein).  Figure 7. 
 
 
At baseline, the mean concentration of AMP in WT hearts (0.0530 +/- 0.0102 
µmol/mg protein) was not significantly different than in CD39TG hearts (0.0252 
+/- 0.0143 µmol/mg protein). The mean concentration of AMP in WT after I/R 
injury (0.0234 +/- 0.0104 µmol/mg protein) was not significantly different than 
Figure 7. HPLC measurements of ADP in WT and CD39TG ex vivo hearts after 30 minutes 
ischemia and 15 minutes reperfusion. N=3/group 	  
AMP levels in CD39TG injured mice (0.0223 +/- 0.0086 µmol/mg protein). (p = 
0.296). Figure 8. 
 
 
At baseline, the mean concentration of adenosine in WT hearts (0.0059 +/- 
0.0012 µmol/mg protein) was not significantly different than adenosine 
concentrations found in CD39TG hearts (0.0067 +/- 0.0012 µmol/mg protein).  
However, following I/R injury there was a significant difference in the adenosine 
concentration in WT hearts (0.0023 +/- 0.0004 µmol/mg protein) verses CD39TG 
hearts (0.0146 +/- 0.0037 µmol/mg protein, p = 0.005).  Indeed, in WT hearts 
Figure 8. HPLC measurements of AMP in WT and CD39TG ex vivo hearts after 30 minutes 
ischemia and 15 minutes reperfusion. N=3/group 	  
adenosine decreases, whereas in CD39TG hearts adenosine increases. Figure 
9. 
  
 
 
RISK Protein Analysis 
To begin to decipher the mechanisms behind the cardioprotection seen with 
CD39 overexpression, Western Blot analysis was performed to examine 
differences in protein activation between wildtype and transgenic mice at 
baseline and after 30 minutes ischemia and 15 minutes reperfusion.  GAPDH 
Figure 9. Summary of HPLC measurements of adenosine in WT and CD39TG ex vivo hearts after 
30 minutes ischemia and 15 minutes reperfusion. N=3/group 	  
was used as a control to ensure equal levels of protein were loaded in each 
sample.  There was no statistical significance (p > 0.05) between GAPDH 
concentrations in WT baseline (307.9 +/- 61.1 arbitrary densitometry units), 
CD39TG baseline (329.4 +/- 38.5 arbitrary densitometry units), Injured WT (326.4 
+/- 37.1 arbitrary densitometry units), and injured CD39TG (294.7 +/- 44.3 
arbitrary densitometry units). Figure 10. 
       
 
 
Given recent publications implicating the RISK pathway in cardioprotection after 
myocardial infarction, protein kinase B (Akt), Extracellular signal-Related Kinase 
(Erk), and glycogen synthase kinase (GSK) total protein levels and 
phosphorylation levels were assessed after 30 minutes ischemia and 15 minutes 
reperfusion.  A time point at 15 minutes reperfusion was used to determine the 
Figure 10. Levels of GAPDH in baseline WT, baseline CD39TG, injured WT, and injured 
CD39TG show no significant difference in protein loading. N= 4/group, p >0.05. 
early modifications of these proteins.  Total Akt protein levels did not change 
between the experimental groups (p > 0.05).  However, wildtype hearts 
demonstrated a significant increase (p<0.001) in Akt serine 473 phosphorylation 
levels (163.9 +/- 13.0 arbitrary densitometry units) after 30 minutes ischemia and 
15 minutes reperfusion compared to baseline WT (16.51 +/- 0.88 arbitrary 
densitometry units).  In addition, CD39 transgenic hearts demonstrated an even 
greater increase (p<0.001) in Akt serine 473 phosphorylation levels after injury 
(Baseline CD39TG: 65.81 +/- 15.71 arbitrary densitometry units, Injured 
CD39TG: 301.2 +/- 11.7 arbitrary densitometry units, Figure 11).  There was also 
a significant difference (p<0.001) between injured WT and injured CD39TG 
showing an increase in phosphorylation and activation of Akt serine in CD39TG 
mice after 30 minutes ischemia and 15 minutes reperfusion.  
 
Figure	  11.	  Data	  from	  Akt	  Western	  blot	  analysis between ex vivo baseline WT, injured WT, 
baseline CD39 TG, and injured CD39 TG mice. N = 4/group	  	  
Although there was an increase in 
phosphorylation of Erk 42 in WT 
injured compared to baseline, the 
difference was not significant, 
(Baseline WT 471.1 +/- 56.2 
arbitrary densitometry units, Injured 
WT 636.2 +/- 87.8 arbitrary 
densitometry units; p > 0.05).  Erk 
42 phosphorylation was significantly 
increased in CD39 transgenic 
hearts after injury compared to 
baseline transgenic levels (Baseline 
CD39TG: 470.1 +/- 68.8 arbitrary 
densitometry units, Injured 
CD39TG: 947.9 +/- 86.2 arbitrary 
densitometry units; p = 0.002).  
 
Phosphorylation of Erk 44 mimicked 
that of Erk 42, Figure 12.  Again, 
there was an increase in 
phosphorylation of Erk 44 in WT 
injured compared to baseline, 
Figure	  12.	  Data	  from	  Erk	  Western	  blot	  analysis between ex vivo baseline WT, injured WT, baseline 
CD39 TG, and injured CD39 TG mice. N = 4/group	  	  
although the difference was not significant (Baseline WT: 326.5 +/- 86.4 arbitrary 
densitometry units, Injured WT: 404.8 +/- 89.1 arbitrary densitometry units, p > 
0.05). Erk 44 phosphorylation was significantly increased in CD39 transgenic 
isolated hearts after injury compared to baseline transgenic levels (Baseline 
CD39TG: 319.7 +/- 70.0 arbitrary densitometry units, Injured CD39TG: 703.4 +/- 
105.3 arbitrary densitometry units, p = 0.031). Total Erk protein levels did not 
change between the experimental groups (p > 0.05) 
 
Next, phosphorylation of GSK, which is downstream in the signaling cascade to 
Akt and Erk 1/2, was examined 
(Figure 13).  Total GSK protein 
levels did not change between 
the experimental groups (p 
>0.05). Although GSK 
phosphorylation did increase 
after injury in WT isolated hearts 
after 30 minutes ischemia and 
15 minutes reperfusion, there 
was not a significant increase 
compared to baseline levels in 
wildtype littermates (baseline 
WT: 85.14 +/- 12.42 arbitrary 
Figure	  13.	  	  A	  schematic	  representation	  of	  the	  adenosine	  receptor	  and	  activation	  of	  the	  RISK	  pathway.	  	  The	  adenosine	  receptor	  is	  a	  seven	  transmembrane	  domain	  receptor.	  	  Once	  the	  receptor	  binds	  adenosine,	  Akt	  and	  Erk	  1/2	  are	  activated	  via	  phosphorylation.	  	  Through	  a	  signaling	  cascade,	  both	  converge	  to	  phosphorylate	  and	  deactivate	  Gsk-­‐3β.	  	  
densitometry units, Injured WT: 202.2 +/- 17.7 
arbitrary densitometry units; p > 0.05). On the 
contrary, CD39TG hearts displayed a significant 
increase in GSK activation after 30 minutes of 
ischemia and 15 minutes of reperfusion, 
(baseline CD39TG: 138.5 +/- 10.3 arbitrary 
densitometry units, injured CD39TG: 342.5 +/- 
65.2 arbitrary densitometry units; p = 0.001), 
Figure 14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure	  14.	  Data	  from	  GSK	  Western	  blot	  analysis between ex vivo baseline WT, injured WT, baseline CD39 TG, and injured CD39 TG mice. N = 4/group	  
Discussion 
Previous research in the laboratory of my advisor, Dr. Richard Gumina, has 
explored cardioprotection in CD39TG mice with global overexpression of human 
ectonucleoside triphosphate diphosphohydrolase 1 (CD39) after in vivo 
myocardial infarction.  The previous data demonstrated a decrease in infarct size 
after 20 or 60 minutes of ischemia followed by 24 hours reperfusion in human 
CD39 TG mice when compared to WT littermates.  Furthermore, in vivo 
activation via phosphorylation of Erk 1/2 protein kinase suggested the RISK 
pathway was one of the mechanisms behind the observed cardioprotection.   	  
The goal of the current work was to determine if global overexpression of human 
CD39 in ex vivo isolated perfusion, without blood and hormonal complications, 
would confer similar cardioprotection to that previously seen in vivo.  
Furthermore, if cardioprotection was observed in the ex vivo Langendorff model, 
our goal was to determine possible mechanisms behind the cardioprotection.   
 
The results of this study demonstrated that overexpression of human CD39 in the 
myocardium alone, without the complicating factor of blood, which includes 
monocytes, immune cells, platelets, and hormones, does indeed protect the 
heart following ex vivo I/R injury.  We hypothesized that the mechanism 
responsible for the observed cardioprotection was due to increased adenosine 
production.  HPLC was used to determine levels of ATP, ADP, AMP, and 
adenosine following ex vivo I/R injury.  There was no statistically significant 
difference between baseline levels of adenine nucleotides in WT and CD39TG 
hearts.  However, as hypothesized, there was a significant increase in adenosine 
levels in injured CD39 transgenic hearts when compared to injured wildtype 
hearts.  These results suggest that the mechanism behind the observed 
cardioprotection does indeed involve increased adenosine generation.  The data 
also showed that there in fact is a decrease in adenosine levels in WT mice after 
injury, although results were not statistically significant.  Adenosine signals 
through four known receptors: A1, A2a, A2b, and A3.  Which receptor adenosine 
signals through depends on cell type, and all adenosine receptors can then 
activate the RISK pathway. Previous research in Dr. Gumina’s lab shows that 
inhibition of all adenosine receptors with 8-SPT blocked the observed 
cardioprotection in CD39TG mice.  Future studies will look into involvement of 
the specific adenosine receptors. 
 
Western blot analysis demonstrated increased phosphorylation of key proteins 
involved in the RISK pathway, Akt, Erk 1/2, and GSK CD39 overexpressing 
mouse hearts following injury.  These results strongly suggest that the RISK 
pathway plays a role in the observed cardioprotection.  Future studies will 
examine if inhibition of these signaling steps abolishes cardiac protection in 
CD39 overexpressing hearts.  
 
This project concludes that cardioprotection is observed in human CD39 
overexpressing isolated mouse hearts subjected to I/R injury when compared to 
wildtype hearts.  Furthermore, this work demonstrated that the mechanisms that 
convey cardioprotection involves increased adenosine generation, as well as 
activation of the RISK pathway.  Further studies are necessary to gain a better 
understanding of the mechanism behind the cardioprotection before CD39 
studies may be applied in a clinical setting.  While previous studies in vivo 
showed that global overexpression protects the heart after I/R injury, my study 
limited overexpression to just the myocytes and vasculature of the heart, and still 
observed protection.  Future studies will examine restricted CD39 
overexpression.  For example, Dr. Gumina’s lab is currently working on mice with 
myocyte specific overexpression of CD39.  Studies with these animals will 
address if it is myocyte expression that is protective. 
 
The ultimate goal of this and other studies done on CD39 would be to translate 
findings into a clinical setting and determine if and how CD39 could possibly be 
used as a therapeutic in organ transplants, stroke, spinal cord injury, and 
myocardial infarction, which all involve ischemia and reperfusion injury.  
However, before this work could be applied to humans, researchers must also 
determine when and how CD39 can be administered to induce organ protection. 
An important question remaining is if CD39 could be administered during a 
period of ischemia or after the onset of reperfusion and still provide 
cardioprotection.  While much research remains before clinical application of 
CD39, these results should indicate that upregulation of CD39 may be an 
approach to reduce I/R injury. 
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